GUIDELINES FOR THE PREVENTION OF PNEUMOCOCCAL DISEASES BY VACCINATION IN PATIENTS WITH CHRONIC RENAL DISEASE

Considering the reported cases of invasive pneumococcal disease in advanced chronic kidney disease patients, in May 2017 the Steering Board of the Croatian Society of Nephrology, Dialysis and Transplantation (CSNDT) of the Croatian Medical Association issued a decision on the preparation of Guidelines for the prevention of pneumococcal diseases in patients with chronic kidney disease. The Guidelines are based on relevant medical literature, Guidelines of the European Society of Clinical Microbiology and Infectious Diseases, the World Association for Infectious Diseases and Immunological Disorders, and the Program for immunization, seroprophylaxis and chemoprophylaxis for special population groups of the Croatian Institute of Public Health. Nephrologists, infectologists and epidemiologists were involved in their development. There are two types of pneumococcal vaccine available in Croatia that can be used for adults, conjugated vaccine PCV13 and polysaccharide vaccine PPSV23. The Guidelines include planning and implementation of vaccination in chronic kidney disease patients who replace kidney function with hemodialysis, peritoneal dialysis, renal transplant, or are candidates for treatment by transplantation, having one or more comorbidities: diabetes mellitus, chronic pulmonary disease, chronic cardiovascular disease, chronic advanced liver disease, chronic kidney disease with solid or hematological tumors, and splenectomy.

Download Full-text

Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience of the German Hepatitis C Registry

Zeitschrift für Gastroenterologie ◽

10.1055/s-0037-1612875 ◽

2018 ◽

Vol 56 (01) ◽

pp. E2-E89

Author(s):

J Wiegand ◽

P Buggisch ◽

S Mauss ◽

K Böker ◽

H Klinker ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Kidney Disease ◽

Chronic Hepatitis C ◽

Real World ◽

Advanced Chronic Kidney Disease

Download Full-text

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

10.32512/jmr.2.1.2019/2.3 ◽

2019 ◽

pp. 2-3

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Estimated Glomerular Filtration Rate ◽

Chronic Kidney Disease Stage ◽

Disease Stage ◽

Phosphate Binders ◽

Advanced Chronic Kidney Disease ◽

Phosphate Retention ◽

Stage 4 ◽

Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Download Full-text

Stroke in chronic renal failure

Orvosi Hetilap ◽

10.1556/oh.2008.28292 ◽

2008 ◽

Vol 149 (15) ◽

pp. 691-696

Author(s):

Dániel Bereczki

Keyword(s):

Risk Factors ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Renal Disease ◽

Chronic Renal Disease ◽

Kidney Diseases ◽

Cerebrovascular Diseases ◽

Lipid Lowering ◽

Increased Risk ◽

Intracerebral Hemorrhages

Chronic kidney diseases and cardiovascular diseases have several common risk factors like hypertension and diabetes. In chronic renal disease stroke risk is several times higher than in the average population. The combination of classical risk factors and those characteristic of chronic kidney disease might explain this increased risk. Among acute cerebrovascular diseases intracerebral hemorrhages are more frequent than in those with normal kidney function. The outcome of stroke is worse in chronic kidney disease. The treatment of stroke (thrombolysis, antiplatelet and anticoagulant treatment, statins, etc.) is an area of clinical research in this patient group. There are no reliable data on the application of thrombolysis in acute stroke in patients with chronic renal disease. Aspirin might be administered. Carefulness, individual considerations and lower doses might be appropriate when using other treatments. The condition of the kidney as well as other associated diseases should be considered during administration of antihypertensive and lipid lowering medications.

Download Full-text